Overview

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Vividion Therapeutics, Inc.